Parkrun as self-managed cardiac rehabilitation: secondary analysis of a cross-sectional survey of parkrun in the UK

Steve Haake,1 Thomas W Johnson,2 Jessica Bourne,3 Helen Quirk,4 Alice Bullas1

ABSTRACT

Objectives Cardiac rehabilitation following a cardiovascular disease (CVD)-related illness has been shown to reduce the risk of heart attack and hospital admission. The American College of Sports Medicine recommends 3–5 days per week of moderate to vigorous exercise. Despite this, only 38% of those eligible complete rehabilitation programmes. Parkrun organises free, weekly, timed, 5 km running or walking events. The aim of this study was to investigate whether parkrun can support self-managed cardiac rehabilitation.

Methods We undertook a secondary analysis of a survey of UK parkrunners, comparing responses of those reporting no health conditions (n=53 967) with those with one or more CVD-related conditions (n=404). Thematic analysis was used to analyse 53 open-ended text comments from the latter.

Results Four hundred and four respondents (0.7% of the total) reported CVD-related conditions with the largest proportions among those walking the event (24% of male participants and 5% of female participants). For those doing <3 days per week of physical activity at registration, 47% increased activity to ≥3 days per week. Among those with CVD-related conditions, participation in parkrun led to perceived improvements in fitness (81% of participants), physical health (80% or participants) and happiness (74% of participants). Two thirds reported improvements to their ability to manage their condition(s) and half to their lifestyle choices. Analysis of 53 open text comments revealed that those with CVD-related conditions used parkrun to monitor their condition and were motivated by encouragement from the parkrun community. Enjoyment and fun were important for engagement, although some individuals were dispirited by poor performance due to some individuals were dispirited by poor performance due to long-term illness. Some commented on the support given by the community.

Conclusions Individuals with CVD-related conditions used parkrun to self-manage their rehabilitation; this applied to those attending parkrun following disease onset as well as those engaged with parkrun prior to their condition. Parkrun, or events with similar characteristics, could support self-managed cardiac rehabilitation.

INTRODUCTION

Cardiovascular disease (CVD) remains the leading cause of death worldwide, representing almost a third of all global deaths; preventative therapies are essential following a diagnosis of CVD. Prevention tends to emphasise pharmacotherapy despite lifestyle factors (including smoking cessation, physical activity and diet) demonstrating strong associations with long-term survival.

A systematic review of longitudinal physical activity showed that maintenance or adoption of an active lifestyle
was associated with a survival advantage. The British Association of Cardiovascular Prevention and Rehabilitation suggests that patients experiencing acute coronary syndrome should be provided with a programme of cardiac rehabilitation that includes supervised exercise, risk factor management, nutritional education and psychosocial support. In terms of the necessary volume of exercise, the American College of Sports Medicine (ACSM) propose that those in cardiac rehabilitation should do 20–60 min of moderate or vigorous aerobic exercise 3–5 days per week. A recent Cochrane review reported that exercise-based cardiac rehabilitation reduces the risk of all-cause mortality, heart attack, hospital re-admission and improves health-related quality of life.

Despite the benefits of rehabilitation programmes, only half of those eligible in the UK actually attend, of which there is a 38% completion rate. Additionally, the COVID-19 pandemic has caused major disruption to cardiac services and some face-to-face cardiac rehabilitation was withdrawn in favour of self-managed options. If cardiac rehabilitation programmes evolve to include self-managed components, the individual, social and environmental factors that encourage engagement and promote long-term adherence need to be identified. Such a programme should have the capability to be implemented at scale to have the greatest impact on population health. Currently, there is only weak evidence to suggest that self-managed interventions positively impact adherence to cardiac rehabilitation.

Parkrun (generally written with a small ‘p’) is a registered charity, which organises free, weekly, timed, 5 km runs or walks at >700 locations in the UK (and across 22 countries). Parkrun has >7 million registrants and hundreds of thousands of regular participants. Events take place each Saturday morning and are organised by volunteers supported by a core team of parkrun employees. Mass running or walking events, such as parkrun, have the potential to improve physical and mental health in large numbers of people and at low cost.

In 2018, a cross-sectional survey was conducted on UK parkrun participants to examine the impact of participation on an individual’s health and well-being. Respondents self-reported whether they were limited by a chronic condition lasting 12 months or more, some of which were CVD-related. A comparison of parkrun participants with and without CVD-related conditions could provide a better understanding of the motivations and potential benefits provided by self-managed, community-based physical activity.

The aim of this paper is to conduct a secondary analysis of the 2018 survey to understand the impact of parkrun on those with CVD-related conditions and consider its potential as a form of self-managed exercise for cardiac rehabilitation.

METHODS

Survey questions

A cross-sectional survey comprising 47 questions was emailed to all UK registered parkrunners aged 16+ years between 29 October and 3 December 2018; 59,999 completed the survey using Qualtrics survey software with findings reported previously. The following questions were used in the current study:

- **Participation type**: participants self-selected ‘runner/walker’, ‘runner/walker and volunteer’, ‘volunteer only’ or ‘registered but not yet participated’.
- **Long-term health conditions**: participants were asked: “Are your day-to-day activities limited because of a health condition or disability which has lasted, or is expected to last, at least 12 months?” Responses were: ‘rather not say, do not know; no; yes, limited a little; yes, limited a lot’. If answering yes, participants were offered a list of 56 health conditions or ‘other’ plus a free-text option.
- **Mental health**: the Short Warwick-Edinburgh Mental Well-being Scale. Responses to seven items were scored from 1 to 5. The total raw scores were transformed into metric scores using the validated protocol identified by the original researchers. Scores range from 7 to 35 with a higher score indicating higher positive mental well-being.
- **Life satisfaction**: Office of National Statistics—“Overall, how satisfied are you with your life nowadays?” An 11-point Visual Analogue Scale (VAS) was given with 0 identified as ‘not at all’ and 10 as ‘completely’.
- **Overall health**: the VAS from the EuroQol-5 survey asked the following: “We would like to know how good or bad your health is TODAY. This scale is numbered from 0 to 100. 100 means the best health you can imagine. 0 means the worst health you can imagine. Please enter a number in the box below to indicate how your health is TODAY”.
- **Activity level**: a bespoke question created by parkrun for the purpose of assessing activity level at parkrun registration asked the following: “Over the last 4 weeks, how often have you done at least 30 min of moderate exercise (enough to raise your breathing rate)?” Possible responses were: ‘less than once per week; about once per week; about twice per week; about three times per week; four or more times per week; rather not say, do not know’.
- **Motives for initial participation**: the researchers created a bespoke question: “What motivated you to first participate at parkrun as a runner or walker?” Respondents could select a maximum of three motives from the 20 offered or ‘other’ and a free-text box.
- **Impact of participation**: the researchers created a bespoke question: “Thinking about the impact of parkrun on your health and well-being, to what extent has running or walking at parkrun changed?” Respondents were given 15 possible responses (plus
other’ and a free-text box) with possible answers ‘much worse, worse, no impact, better and much better’.

Open-text comments: open-text responses were prompted by the following: “If there is anything else you would like to mention about the impact of parkrun on your health and well-being, please insert your comments here”.

Demographics
Respondents were matched to the parkrun database to give age, gender, years registered, number of parkruns completed, mean 5 km time in min, index of multiple deprivation (IMD: derived from postcode provided at registration) and activity level at registration.

Participants were segmented by 5 km time from front runners with mean 5 km times <20 min to walkers with mean 5 km times ≥50 min. Ten categories 2.5 min wide were used to categorise participants ≥20 and <45 min, plus a further category 5 min wide for runners/walkers: this made 15 categories in all. This segmentation was used to assess the prevalence of CVD-related conditions from fastest to slowest parkrunner using the median time for each category.

Quantitative data: statistical analysis
Data were initially assessed using Microsoft Excel (for Mac V.16.46) using descriptors (counts, averages, ranges, skewness and kurtosis) and duplicates were removed by searching for identical combinations of age, gender, home parkrun and parkrun. Free text was redacted to remove any personally identifying words. The analysis included only those who identified as runners/walkers or runners/walkers who volunteer: those who volunteered only were excluded. Not all questions were compulsory and matching of survey data to parkrun data was not total. Thus, counts vary for each question are specified in all tables.

Responses for the impact question were dichotomised into ‘not improved’ (0: ‘much worse’, ‘worse’ and ‘no impact’) and ‘improved’ (1: ‘better’ and ‘much better’).

Those who answered ‘no’ to the health conditions question were coded as 0; those who answered ‘yes, limited a little’ or ‘yes, limited a lot’ were coded as 1. The following conditions (using the survey descriptors) were selected as CVD-related conditions:

1. Coronary artery disease (including angina, peripheral vascular disease).
2. Heart condition including arrhythmia (abnormal heart rate) or atrial fibrillation (irregular heart rate).
3. Heart failure.
4. Stroke (trans-ischaemic attack and cerebrovascular accident).
5. Venous thromboembolism (deep venous thrombosis and pulmonary embolism).

Individuals who were identified as having a CVD-related condition were compared with those reporting no health conditions. Averages were compared using Mann-Whitney U tests with effect size calculated using $r=Z^2/n$, where $Z$ is the standardised test statistic and $n$ is the number of ranked respondents. Differences between categorical data were calculated using the $\chi^2$ test with effect size calculated using $\phi^2=\chi^2/n(k-1)$, where $\chi^2$ is the test statistic, $n$ is the number of respondents and $k-1$ is the number of rows or columns (whichever is the smaller).

Qualitative data: thematic analysis
Open-text comments were extracted for thematic analysis if they had one or more CVD-related condition using Microsoft Excel V.26. The approach was an iterative process carried out by author SH as follows:

1. Familiarisation with the data by reading through the comments several times.
2. Creation of a conceptual framework of a priori themes generated by selecting the most commonly selected motives (eg, fitness), the impacts showing greatest proportions with improvement (eg, sense of personal achievement) and those impacts or motives where statistical analysis showed differences between those with CVD-related conditions and no conditions (eg, being active in a safe environment).
3. Rereading of the comments and allocation of quotes to the a priori themes.
4. Reviewing and revising the a priori themes including generation of additional themes arising from the data.
5. Additional reading of the comments to allocate appropriate verbatim quotes to subthemes.
6. Rereading of the comments and quotes to check intratheme and intrasubtheme consistency.
7. Removal of themes with zero comments, and collapse of smallest themes into larger ones where relevant.

Comments were categorised into new parkrunners (registered 2 years or less) or long-term parkrunners (registered >2 years). Their participation was categorised as occasional (1–4 parkruns per year), regular (5–12 parkruns per year) or committed (>12 parkruns per year). The number of parkruns per year was only calculated for those registered at least a year (since periods <1 year tended to give artificially large values).

RESULTS
Demographics
There were 445 CVD-related conditions from 404 participants or 0.7% of the total sample (online supplemental file S1, table 1); 53 967 reported that they had no health conditions. Of those with CVD-related conditions, 37% had arrhythmia or atrial fibrillation, 24% had coronary artery disease, 23% had a stroke, 20% had heart failure and 6.1% had venous thromboembolism.

Table 1 shows that participants with CVD-related conditions compared with those with no health conditions tended to be older (median 62.9 vs 48.6 years), male (75.4% vs 51.4%) and registered longer with parkrun (median 3.3 vs 2.6 years) and completed a similar number of parkruns per year (11 and 12, respectively). The IMD
Table 1  Demographics of participants with CVD-related conditions (lasting 12 months or more) compared with participants with no health conditions for runners/walkers and runners/walkers who volunteer

<table>
<thead>
<tr>
<th></th>
<th>No health conditions</th>
<th>All cardiovascular disease-related conditions</th>
<th>Coronary artery disease (including angina peripheral vascular disease)</th>
<th>Heart condition (including arrhythmia (abnormal heart rate) or atrial fibrillation (irregular heart rate))</th>
<th>Heart failure</th>
<th>Stroke (trans-ischaemic attack and cerebrovascular accident)</th>
<th>Venous thromboembolism (deep venous thrombosis and pulmonary embolism)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>n</td>
<td>53 625</td>
<td>401</td>
<td>95</td>
<td>149</td>
<td>80</td>
<td>93</td>
</tr>
<tr>
<td></td>
<td>Median (IQR)</td>
<td>48.6 (18.5)</td>
<td>62.9 (15.5)</td>
<td>65.0 (11.1)</td>
<td>63.7 (17.3)</td>
<td>63.8 (15.9)</td>
<td>60.2 (12.7)</td>
</tr>
<tr>
<td></td>
<td>Mean (SD)</td>
<td>47.64 (13.00)</td>
<td>60.86 (11.37)</td>
<td>64.09 (8.53)</td>
<td>60.95 (12.41)</td>
<td>61.46 (11.76)</td>
<td>58.89 (11.31)</td>
</tr>
<tr>
<td></td>
<td>P value</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>Test statistic</td>
<td>19.44</td>
<td>11.98</td>
<td>11.70</td>
<td>9.05</td>
<td>8.12</td>
<td>3.35</td>
</tr>
<tr>
<td></td>
<td>Effect size</td>
<td>0.08</td>
<td>0.05</td>
<td>0.05</td>
<td>0.04</td>
<td>0.04</td>
<td>0.01</td>
</tr>
<tr>
<td>Gender</td>
<td>n</td>
<td>42 146</td>
<td>325</td>
<td>76</td>
<td>124</td>
<td>58</td>
<td>78</td>
</tr>
<tr>
<td></td>
<td>% female</td>
<td>51.4%</td>
<td>24.6%</td>
<td>15.8%</td>
<td>24.2%</td>
<td>10.3%</td>
<td>34.6%</td>
</tr>
<tr>
<td></td>
<td>% male</td>
<td>75.4%</td>
<td>84.2%</td>
<td>75.8%</td>
<td>89.7%</td>
<td>65.4%</td>
<td>57.1%</td>
</tr>
<tr>
<td></td>
<td>P value</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>0.003</td>
</tr>
<tr>
<td></td>
<td>Test statistic</td>
<td>92.30</td>
<td>38.41</td>
<td>36.51</td>
<td>38.99</td>
<td>8.73</td>
<td>0.61</td>
</tr>
<tr>
<td></td>
<td>Effect size</td>
<td>0.04</td>
<td>0.03</td>
<td>0.03</td>
<td>0.03</td>
<td>0.01</td>
<td>0.01</td>
</tr>
<tr>
<td>IMD</td>
<td>n</td>
<td>41 632</td>
<td>319</td>
<td>75</td>
<td>117</td>
<td>60</td>
<td>78</td>
</tr>
<tr>
<td>Q1</td>
<td>9.2%</td>
<td>8.8%</td>
<td>5.3%</td>
<td>6.8%</td>
<td>10.0%</td>
<td>10.3%</td>
<td>14.3%</td>
</tr>
<tr>
<td>Q2</td>
<td>20.2%</td>
<td>19.4%</td>
<td>18.7%</td>
<td>23.9%</td>
<td>20.0%</td>
<td>20.5%</td>
<td>9.5%</td>
</tr>
<tr>
<td>Q3</td>
<td>30.0%</td>
<td>36.1%</td>
<td>34.7%</td>
<td>36.8%</td>
<td>41.7%</td>
<td>37.2%</td>
<td>14.3%</td>
</tr>
<tr>
<td>Q4</td>
<td>40.6%</td>
<td>35.7%</td>
<td>41.3%</td>
<td>32.5%</td>
<td>28.3%</td>
<td>32.1%</td>
<td>61.9%</td>
</tr>
<tr>
<td>P value</td>
<td>0.119</td>
<td>0.598</td>
<td>0.160</td>
<td>0.174</td>
<td>0.420</td>
<td>0.119</td>
<td>0.61</td>
</tr>
<tr>
<td></td>
<td>Test statistic</td>
<td>5.86</td>
<td>1.88</td>
<td>5.16</td>
<td>4.98</td>
<td>2.18</td>
<td>5.86</td>
</tr>
<tr>
<td></td>
<td>Effect size</td>
<td>0.01</td>
<td>0.01</td>
<td>0.01</td>
<td>0.01</td>
<td>0.01</td>
<td>0.01</td>
</tr>
<tr>
<td>Activity level at registration</td>
<td>n</td>
<td>38 614</td>
<td>284</td>
<td>69</td>
<td>104</td>
<td>53</td>
<td>72</td>
</tr>
<tr>
<td>&lt;1</td>
<td>4.9%</td>
<td>5.6%</td>
<td>1.4%</td>
<td>3.8%</td>
<td>1.9%</td>
<td>11.1%</td>
<td>11.8%</td>
</tr>
<tr>
<td>=1</td>
<td>11.4%</td>
<td>9.5%</td>
<td>5.8%</td>
<td>9.6%</td>
<td>11.3%</td>
<td>15.3%</td>
<td>5.9%</td>
</tr>
<tr>
<td>=2</td>
<td>22.9%</td>
<td>20.1%</td>
<td>18.8%</td>
<td>16.3%</td>
<td>20.8%</td>
<td>19.4%</td>
<td>23.5%</td>
</tr>
<tr>
<td>&gt;3</td>
<td>33.9%</td>
<td>31.0%</td>
<td>34.8%</td>
<td>26.0%</td>
<td>32.1%</td>
<td>36.1%</td>
<td>35.3%</td>
</tr>
<tr>
<td>&gt;4</td>
<td>27.0%</td>
<td>33.8%</td>
<td>39.1%</td>
<td>44.2%</td>
<td>34.0%</td>
<td>18.1%</td>
<td>23.5%</td>
</tr>
<tr>
<td>P value</td>
<td>0.099</td>
<td>0.098*</td>
<td>0.003</td>
<td>0.719*</td>
<td>0.055*</td>
<td>0.700*</td>
<td>0.700*</td>
</tr>
<tr>
<td></td>
<td>Test statistic</td>
<td>7.79</td>
<td>7.84</td>
<td>15.85</td>
<td>2.09</td>
<td>9.27</td>
<td>2.20</td>
</tr>
<tr>
<td></td>
<td>Effect size</td>
<td>0.01</td>
<td>0.01</td>
<td>0.02</td>
<td>0.01</td>
<td>0.02</td>
<td>0.01</td>
</tr>
<tr>
<td>Total parkruns</td>
<td>n</td>
<td>41 277</td>
<td>320</td>
<td>75</td>
<td>123</td>
<td>57</td>
<td>76</td>
</tr>
<tr>
<td>Median (IQR)</td>
<td>21 (56)</td>
<td>20.5 (93)</td>
<td>12 (95)</td>
<td>25 (97)</td>
<td>17 (81)</td>
<td>17 (66)</td>
<td>17 (44)</td>
</tr>
<tr>
<td>Mean±SD</td>
<td>46.03 (60.84)</td>
<td>58.22 (4.31)</td>
<td>49.48 (64.99)</td>
<td>61.85 (76.64)</td>
<td>53.25 (70.45)</td>
<td>53.04 (77.26)</td>
<td>51.33 (73.98)</td>
</tr>
<tr>
<td>P value</td>
<td>0.194</td>
<td>0.305</td>
<td>0.152</td>
<td>0.939</td>
<td>0.696</td>
<td>0.962</td>
<td>0.062</td>
</tr>
<tr>
<td></td>
<td>Test statistic</td>
<td>1.30</td>
<td>1.026</td>
<td>1.43</td>
<td>0.077</td>
<td>0.39</td>
<td>0.05</td>
</tr>
<tr>
<td></td>
<td>Effect size</td>
<td>0.01</td>
<td>0.01</td>
<td>0.01</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>Years registered</td>
<td>n</td>
<td>42 146</td>
<td>325</td>
<td>76</td>
<td>124</td>
<td>58</td>
<td>78</td>
</tr>
<tr>
<td>Median (IQR)</td>
<td>2.62 (3.86)</td>
<td>3.26 (4.52)</td>
<td>2.86 (4.02)</td>
<td>4.14 (5.01)</td>
<td>2.52 (4.47)</td>
<td>2.10 (4.57)</td>
<td>1.31 (4.09)</td>
</tr>
<tr>
<td>Mean±SD</td>
<td>3.13 (2.52)</td>
<td>3.68 (2.95)</td>
<td>3.50 (2.77)</td>
<td>4.25 (3.07)</td>
<td>3.23 (2.71)</td>
<td>3.06 (2.81)</td>
<td>2.91 (2.94)</td>
</tr>
<tr>
<td>P value</td>
<td>0.003</td>
<td>0.258</td>
<td>&lt;0.001</td>
<td>0.916</td>
<td>0.510</td>
<td>0.497</td>
<td>0.001</td>
</tr>
</tbody>
</table>

Continued
Table 1  Continued

<table>
<thead>
<tr>
<th>Test statistic</th>
<th>No health conditions</th>
<th>All cardiovascular disease-related conditions</th>
<th>Coronary artery disease (including angina peripheral vascular disease)</th>
<th>Heart condition (including arrhythmia (abnormal heart rate) or atrial fibrillation (irregular heart rate))</th>
<th>Heart failure</th>
<th>Stroke (trans-ischaemic attack and cerebrovascular accident)</th>
<th>Venous thromboembolism (deep venous thrombosis and pulmonary embolism)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.97</td>
<td>1.13</td>
<td>4.09</td>
<td>0.11</td>
<td>0.66</td>
<td>0.680</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.01</td>
<td>0.01</td>
<td>0.02</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Parkruns per year (only those registered >1 year)

<table>
<thead>
<tr>
<th>n</th>
<th>Median (IQR)</th>
<th>Mean±SD</th>
<th>P value</th>
<th>Test statistic</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>30 909</td>
<td>11.3 (19.2)</td>
<td>14.62 (12.12)</td>
<td>0.631</td>
<td>0.48</td>
<td>0.01</td>
</tr>
<tr>
<td>251</td>
<td>12.4 (20.4)</td>
<td>14.63 (12.43)</td>
<td>0.070</td>
<td>1.81</td>
<td>0.01</td>
</tr>
<tr>
<td>60</td>
<td>8.82 (19.5)</td>
<td>12.66 (12.46)</td>
<td>0.311</td>
<td>1.01</td>
<td>0.01</td>
</tr>
<tr>
<td>106</td>
<td>11.3 (19.0)</td>
<td>14.03 (12.55)</td>
<td>0.917</td>
<td>0.10</td>
<td>0.00</td>
</tr>
<tr>
<td>43</td>
<td>12.4 (20.3)</td>
<td>14.30 (11.66)</td>
<td>0.909</td>
<td>0.11</td>
<td>0.234</td>
</tr>
<tr>
<td>53</td>
<td>12.9 (23.4)</td>
<td>15.18 (12.60)</td>
<td>0.815</td>
<td>0.11</td>
<td>0.234</td>
</tr>
<tr>
<td>15</td>
<td>11.5 (22.1)</td>
<td>15.46 (13.27)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Activity level at survey

<table>
<thead>
<tr>
<th>Activity level</th>
<th>n</th>
<th>Median (IQR)</th>
<th>Mean±SD</th>
<th>P value</th>
<th>Test statistic</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;1</td>
<td>53 898</td>
<td>11.3 (19.2)</td>
<td>14.62 (12.12)</td>
<td>0.002</td>
<td>0.48</td>
<td>0.01</td>
</tr>
<tr>
<td>≈1</td>
<td>403</td>
<td>12.4 (20.4)</td>
<td>14.63 (12.43)</td>
<td>0.020</td>
<td>1.81</td>
<td>0.01</td>
</tr>
<tr>
<td>≈2</td>
<td>96</td>
<td>8.82 (19.5)</td>
<td>12.66 (12.46)</td>
<td>0.631</td>
<td>1.01</td>
<td>0.01</td>
</tr>
<tr>
<td>≈3</td>
<td>150</td>
<td>11.3 (19.0)</td>
<td>14.03 (12.55)</td>
<td>0.917</td>
<td>0.10</td>
<td>0.00</td>
</tr>
<tr>
<td>&gt;4</td>
<td>80</td>
<td>12.4 (20.3)</td>
<td>14.30 (11.66)</td>
<td>0.909</td>
<td>0.11</td>
<td>0.234</td>
</tr>
</tbody>
</table>

Activity change between registration and survey

<table>
<thead>
<tr>
<th>Activity change</th>
<th>n</th>
<th>Median (IQR)</th>
<th>Mean±SD</th>
<th>P value</th>
<th>Test statistic</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>Decreased</td>
<td>38 570</td>
<td>11.3 (19.2)</td>
<td>14.62 (12.12)</td>
<td>0.002</td>
<td>0.48</td>
<td>0.01</td>
</tr>
<tr>
<td>−4</td>
<td>251</td>
<td>12.4 (20.4)</td>
<td>14.63 (12.43)</td>
<td>0.020</td>
<td>1.81</td>
<td>0.01</td>
</tr>
<tr>
<td>−3</td>
<td>60</td>
<td>8.82 (19.5)</td>
<td>12.66 (12.46)</td>
<td>0.631</td>
<td>1.01</td>
<td>0.01</td>
</tr>
<tr>
<td>−2</td>
<td>106</td>
<td>11.3 (19.0)</td>
<td>14.03 (12.55)</td>
<td>0.917</td>
<td>0.10</td>
<td>0.00</td>
</tr>
<tr>
<td>−1</td>
<td>43</td>
<td>12.4 (20.3)</td>
<td>14.30 (11.66)</td>
<td>0.909</td>
<td>0.11</td>
<td>0.234</td>
</tr>
<tr>
<td>No change</td>
<td>53</td>
<td>12.4 (20.3)</td>
<td>14.30 (11.66)</td>
<td>0.909</td>
<td>0.11</td>
<td>0.234</td>
</tr>
<tr>
<td>1</td>
<td>53 898</td>
<td>11.3 (19.2)</td>
<td>14.62 (12.12)</td>
<td>0.002</td>
<td>0.48</td>
<td>0.01</td>
</tr>
<tr>
<td>2</td>
<td>403</td>
<td>12.4 (20.4)</td>
<td>14.63 (12.43)</td>
<td>0.020</td>
<td>1.81</td>
<td>0.01</td>
</tr>
<tr>
<td>3</td>
<td>96</td>
<td>8.82 (19.5)</td>
<td>12.66 (12.46)</td>
<td>0.631</td>
<td>1.01</td>
<td>0.01</td>
</tr>
<tr>
<td>4</td>
<td>150</td>
<td>11.3 (19.0)</td>
<td>14.03 (12.55)</td>
<td>0.917</td>
<td>0.10</td>
<td>0.00</td>
</tr>
<tr>
<td>Increased</td>
<td>80</td>
<td>12.4 (20.3)</td>
<td>14.30 (11.66)</td>
<td>0.909</td>
<td>0.11</td>
<td>0.234</td>
</tr>
<tr>
<td>1</td>
<td>53 898</td>
<td>11.3 (19.2)</td>
<td>14.62 (12.12)</td>
<td>0.002</td>
<td>0.48</td>
<td>0.01</td>
</tr>
<tr>
<td>2</td>
<td>403</td>
<td>12.4 (20.4)</td>
<td>14.63 (12.43)</td>
<td>0.020</td>
<td>1.81</td>
<td>0.01</td>
</tr>
<tr>
<td>3</td>
<td>96</td>
<td>8.82 (19.5)</td>
<td>12.66 (12.46)</td>
<td>0.631</td>
<td>1.01</td>
<td>0.01</td>
</tr>
<tr>
<td>4</td>
<td>150</td>
<td>11.3 (19.0)</td>
<td>14.03 (12.55)</td>
<td>0.917</td>
<td>0.10</td>
<td>0.00</td>
</tr>
</tbody>
</table>
| Life satisfaction
| n              | 53 967| 11.3 (19.2)  | 14.62 (12.12) | 0.002 | 0.48           | 0.01        |
| Median (IQR)    | 8 (2) | 8 (2)        | 8 (2)    | 8 (2)  | 8 (2)         |             |
| Mean±SD         | 7.84 (1.40) | 7.43 (1.79)   | 7.64 (1.74) | 7.39 (1.62) | 7.04 (1.96) | 7.30 (2.08) | 7.08 (2.08) |
| P value         | <0.001 | 0.380        | 0.002    | <0.001 | 0.380        | 0.002       | 0.015     |
| Test statistic  | 41.3% | 43.5%        | 43.5%    | 43.5% | 43.5%        | 43.5%       | 43.5%     |
| Effect size     | 0.03  | 0.02         | 0.02     | 0.02  | 0.02         | 0.02        | 0.02      |

Health VAS 0–100

| n              | 51 577| 11.3 (19.2)  | 14.62 (12.12) | 0.002 | 0.48           | 0.01        |
| Median (IQR)    | 85 (15) | 75 (19)       | 73 (15)    | 75 (15) | 70 (20)       | 75 (20)     | 72.5 (19) |
| Mean±SD         | 82.14 (11.67) | 71.15 (15.58) | 72.12 (13.98) | 72.81 (14.75) | 67.35 (15.54) | 68.29 (17.63) | 67.71 (17.44) |

Continued
profile did not differ between groups, with greater than two-thirds of all respondents in the two least deprived quartiles. Activity levels at registration were similar for both groups with 35.2% of those with CVD-related conditions doing <3 days of physical activity per week.

Figure 1 shows the prevalence of CVD-related conditions for male and female participants segmented by 5 km completion time (see also online supplemental file S1, table 3). The number of participants is shown in figure 1A, the number of participants with CVD-related conditions in figure 1B and the ratio between them in figure 1C (ie, the proportion with a CVD-related condition). Figure 1A, B show that the number of male participants reached a peak at around 30 min, while for female participants, it reached a peak around 35 min. The distribution for both genders had positive skew with a tail of runner/walkers and walkers. Figure 1C shows that the proportion of those with CVD-related conditions increased with completion time to 24% of male walkers and 5% of female walkers.

### Table 1

<table>
<thead>
<tr>
<th></th>
<th>No health conditions</th>
<th></th>
<th>All cardiovascular disease-related conditions</th>
<th></th>
<th>Coronary artery disease (including angina peripheral vascular disease)</th>
<th></th>
<th>Heart condition (including arrhythmia (abnormal heart rate) or atrial fibrillation (irregular heart rate))</th>
<th></th>
<th>Heart failure</th>
<th></th>
<th>Stroke (trans-ischaemic attack and cerebrovascular accident)</th>
<th></th>
<th>Venous thromboembolism (deep venous thrombosis and pulmonary embolism)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>P value</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>&lt;0.001</td>
<td></td>
<td>&lt;0.001</td>
<td></td>
<td>&lt;0.001</td>
<td></td>
<td>&lt;0.001</td>
<td></td>
<td>&lt;0.001</td>
<td></td>
<td>&lt;0.001</td>
<td></td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td><strong>Test statistic</strong></td>
<td>15.04</td>
<td></td>
<td>7.43</td>
<td></td>
<td>8.12</td>
<td></td>
<td>8.45</td>
<td></td>
<td>8.32</td>
<td></td>
<td>4.72</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Effect size</strong></td>
<td>0.07</td>
<td></td>
<td>0.03</td>
<td></td>
<td>0.04</td>
<td></td>
<td>0.04</td>
<td></td>
<td>0.04</td>
<td></td>
<td>0.02</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**SWEDWMBS**

<table>
<thead>
<tr>
<th></th>
<th>n</th>
<th>50 763</th>
<th>371</th>
<th>87</th>
<th>139</th>
<th>69</th>
<th>85</th>
<th>24</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median (IQR)</td>
<td>25.0 (4.69)</td>
<td>24.1 (6.3)</td>
<td>25.0 (4.7)</td>
<td>24.1 (5.5)</td>
<td>24.1 (5.8)</td>
<td>23.2 (5.3)</td>
<td>24.1 (7.5)</td>
<td></td>
</tr>
<tr>
<td>Mean±SD</td>
<td>0.001</td>
<td>0.764</td>
<td>0.073</td>
<td>0.036</td>
<td>0.001</td>
<td>0.181</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Test statistic</strong></td>
<td>3.38</td>
<td>0.30</td>
<td>1.79</td>
<td>2.10</td>
<td>3.75</td>
<td>1.34</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Effect size</strong></td>
<td>0.01</td>
<td>0.00</td>
<td>0.01</td>
<td>0.01</td>
<td>0.02</td>
<td>0.01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Counts are given to indicate how many answered each question since not all questions were compulsory.

*10% cells have expected count <5.
†40% of cells have expected count <5.
‡27.8% of cells have expected count <5.
CVD: cardiovascular disease; IMD, index of multiple deprivation.

---

### Physical activity, health and well-being

Both individuals with CVD-related conditions and those with no health conditions showed increased levels of physical activity (table 1). Specifically, 36.5% of those with CVD-related conditions increased their physical activity levels while 41.3% of individuals with no health conditions reported an increase. Conversely, 21.3% of those with CVD-related conditions reported a decrease in physical activity which was higher than those with no health conditions (16.0%).

Further analysis (online supplemental file S1, table 2) shows that, of the 35.2% with CVD-related conditions doing <3 days of activity per week at registration, 47.5% of them increased their activity to 3 or more days per week by the time of the survey.

Compared with those with no health conditions, having a CVD-related condition was associated with reduced scores of life satisfaction (7.43 vs 7.84), health VAS (71.15 vs 71.52), and SWEDWMBS (25.0 vs 25.02).

---

**Figure 1** (A) Total count in each time category; (B) count within each time category for those with CVD-related conditions and (C) percentage of those with a CVD-related condition as a proportion of the total in each time category (B divided by A). CVD, cardiovascular disease.
Health care delivery, economics and global health care

vs 82.14) and mental well-being (24.27 vs 25.02), although effect sizes tended to be small.

Motives

Figure 2A shows motives for first participating in parkrun for those with CVD-related conditions compared with those with no health conditions (see also online supplemental file S1, table 4). The most frequently chosen motives for both groups were “to contribute to my fitness” and “to contribute to my physical health”. In addition, individuals with CVD-related conditions commonly reported using parkrun as a means to managing their health condition, disability or illness (26%). This group were also motivated ‘to be active in a safe environment’ (8%) compared with 4% of those with no health condition. They were also more likely to choose “a health professional advised me to”, although this was only 2% of the cohort. Conversely, those with CVD-related conditions were less likely to choose ‘to contribute to my fitness’ (49% vs 57%) and ‘to get a recorded time for a 5k’ (12% vs 22%).

Figure 2B compares motives for female and male participants with CVD-related conditions; due to low numbers, statistical significance was set at p<0.05. There were common motives between male and female participants including a desire to improve physical health and manage their health conditions. However, some motivational differences were identified. Specifically, female participants selected more frequently than male participants “my friends, family or colleagues encouraged me to” (15 vs 7%) and ‘to be active in a safe environment’ (14 vs 5%). Male participants selected more frequently than female participants ‘to compete with others’ (14% vs 3%).

Perceived impact of parkrun participation

Figure 3 shows the proportions of respondents reporting improvements in a range of outcomes (see also online
supplemental file S1, table 5). The largest proportions reporting improvements reflect the most commonly selected motives, that is, ‘fitness’, ‘physical health’ and a ‘sense of personal achievement’. Two-thirds of those with CVD-related conditions reported improvements in the management of their condition, disability or illness and half improved their ability to control their weight and lifestyle choices.

The presence of a CVD-related condition (figure 3A) reduced the proportions reporting improvements for all but one measure (“the number of new people you meet’, although not significantly different), in comparison with those without a health condition. Specifically, proportions were lower for those with a CVD-related condition compared with those with no health conditions for the following: ‘fitness’ (81% vs 90%), ‘a sense of personal achievement’ (78% vs 91%), ‘mental health’ (59% vs 69%), ‘enjoyment of competition’ (61% vs 74%), ‘happiness’ (71% vs 79%) and ‘confidence’ (53% vs 61%).

Figure 3B compares perceived impact for female and male participants with CVD-related conditions; due to the low numbers, statistical significance was set at p<0.05. Female participants with CVD-related conditions were more likely than male participants to select improved ‘mental health’ (73 vs 54%), ‘the ability to spend more time outdoors’ (81% vs 65%) and ‘be active in a safe environment’ (69% vs 50%). In comparison, more male than female participants identified the ‘enjoyment of competing’ as an impact (65% vs 51%).

**QUALITATIVE OUTCOMES: THEMATIC ANALYSIS**

Open-text comments were received from 53 participants with CVD-related conditions (15% of those reporting CVD-related conditions). Almost half of the comments came from those who were new parkrunners (registered <2 years) and there was a mix of occasional (19), regular (7) and committed (16) participants. Six themes were identified: (1) community; (2) fitness; (3) encouragement; (4) enjoyment; (5) managing the health condition and (6) performance. Table 2 outlines the themes and subthemes and gives sample verbatim quotes.

Comments on community from both new and long-term parkrunners reflected views about the social context, parkrun’s overarching atmosphere, philosophy and inclusiveness, the camaraderie and the commitment it engenders (table 2.1, a–d). Parkrun was considered a general way to keep fit and active, regardless of whether the participant was using it for rehabilitation or not (table 2.2).

Participants often mentioned encouragement from others at parkrun and encouragement from health professionals was mentioned, for instance: “both my cardiologist and GP support me doing this activity”. Enjoyment was commented on by many (eg, “Park run give me a feel good factor” (s10)) while a feeling of satisfaction was found for at least one participant in the process of rehabilitation: “After quite a heavy operation in April I have been very pleased to be able to return to park running”.

The theme of “managing my health condition” showed evidence of rehabilitation at parkrun with medication being balanced with fitness with one participant (ID 47443) describing how participation in parkrun had led to reductions in medication following a lowered resting heart rate.

Finally, comments about competition revealed how some participants felt they were competing against themselves or about the feeling that parkrun was a low-pressure environment. Some with CVD-related conditions, however, were frustrated at their poor performance with one participant saying, “I was so slow it depressed me”.

**DISCUSSION**

Our analysis identified 0.7% of parkrunners reporting CVD-related conditions, demonstrating that this population do participate in parkrun, although with a much lower disease prevalence than the general population.20 Given that heart disease effects 8.5% of men and 5.4% of women in the UK,7 individuals with CVD-related conditions are under-represented in parkrun. Barriers to parkrun adoption by both individual and healthcare professionals may include the perception that parkrun is for individuals who are already fit, combined with a potential fear of disease exacerbation. In the current survey, only 2% said that parkrun was recommended by a healthcare professional. Despite this, our qualitative analysis revealed that encouragement from healthcare professionals was an important motivation for participation, allowing them to monitor fitness, physiological changes such as resting heart rate and the reduction of medication usage.

Since the survey, the Royal College of General Practitioners and parkrun have set up ‘parkrun practice’ with around 1800 general practitioner (GP) practices in the UK registered; the aim is for GP practices to recommend parkrun to their patients.21 Encouragement and monitoring by healthcare professionals could mitigate for health-related risks and give individuals the confidence to participate. Further research should investigate the perceived barriers to increased physical activity, both for individuals with CVD and healthcare professionals prescribing exercise.

Three-quarters of parkrunners with CVD-related conditions were male participants, despite an equitable split of respondents in the overall survey. While there were several similarities in the motivations for taking part in parkrun between genders (ie, improve physical health, improve fitness), important differences were observed. Male participants were more motivated to engage in parkrun for competition, while female participants were motivated by exercising in a safe environment, being outdoors and improving their mental health. These gender differences must be considered when promoting self-managed cardiac rehabilitation and referring patients to parkrun. Further qualitative research is needed to explore these
<table>
<thead>
<tr>
<th>Theme</th>
<th>Subthemes</th>
<th>Full comments</th>
<th>Participant characteristics</th>
</tr>
</thead>
</table>
| 1. Community: value placed on being part of the parkrun community (n=16) | a. Belonging to a community (n=6) | “I had a major heart attack/cardiac arrest two years ago from which I all but died. It has been a long road back to health. My GP recommended Parkrun to me. It’s a fantastic organisation and has made an immense difference to my recovery in terms of my overall health, fitness, confidence, well being etc. The camaraderie and support of the participants has been invaluable, and I appreciate the new friends I’ve made through it. I’d recommend it to anyone and I hope my survey answers convey all this adequately!” (Participant 69735) | ► New committed parkrunner  
► Male, aged 58 years, IMD Q4  
► Heart failure  
► 69 parkruns in 2.0 years  
► From ≈2 to >2 days per week  
► Evidence of rehabilitation at parkrun |
| | b. Taking part with other people (n=6) | “well organised event every week with no pressure or onus to attend. great social outing amazing amount of different people you meet. help to keep your fitness level up with the added incentive to compete against the clock”. (Participant 87977) | ► New committed parkrunner  
► Male, aged 63 years, IMD Q2  
► Heart condition (including arrhythmia/AF)  
► 72 parkruns in 2.1 years  
► ≈2 to >2 days per week |
| | c. Commitment to the community (n=2) | “There is a commitment to take part, and to volunteer, for your self and for others”. (Participant 1606) | ► Long-term occasional parkrunner  
► Female, aged 63 years  
► Heart condition (including arrhythmia/AF)  
► 21 parkruns in 6.5 years  
► ≈2 to >3 days per week |
| | d. Perceived inclusivity of the community (n=2) | “I live in (…).Canada. The nearest Parkrun is a 30 minute drive away (…). I am hoping there will be a Parkrun that opens closer to my home (…) so that I won’t have to drive to get to it. I would love it to be part of “my” neighbourhood, and will definitely volunteer as well as run. I love the philosophy and inclusiveness of Parkrun. I would like to see more walkers, families, joggers-walkers taking part. Right now most participants are pretty competitive, and the walkers do not come back”. (Participant 25297) | ► Long-term occasional parkrunner  
► Female, aged 63 years, IMD Q4  
► Coronary artery disease  
► 10 parkruns in 4.2 years  
► >≈2 to >3 days per week |
| 2. Fitness: using parkrun to build fitness (n=15) | a. Perceived improvements to general health (n=8) | “Having been a runner for many years the ageing process and medical conditions I have prevented me from enjoying my running as much as I used to. Fortunately parkruns have enabled me to keep fit and active as well as all the other benefits”. (Participant 27647) | ► Long-term committed parkrunner  
► Male, aged 74 years, IMD Q3  
► Heart condition (including arrhythmia/AF) and hypertension  
► 136 parkruns in 6.4 years  
► ≈2 to >4 days per week  
► Evidence of rehabilitation at parkrun |
| | b. Parkrun for rehabilitation (n=4) | “As I am in phase 4 of my Cardiac Rehab, using parkrun to measure improvements to my fitness”. (Participant 27647) | ► Long-term occasional parkrunner  
► Male, aged 66 years, IMD Q3  
► Heart condition (including arrhythmia/AF) and heart failure  
► 5 parkruns in 5.9 years  
► ≈2 to >4 days per week  
► Evidence of rehabilitation at parkrun |
| | c. With fitness comes confidence (n=3) | “From a position of low confidence after a heart attack I now feel able to turn up to a Park Run and take part without any problems. This brings together fitness, ability and confidence. I can turn up on my own or with friends. I have met and made new friends as a result of getting involved in running at a Park Run”. (Participant 28374) | ► New occasional parkrunner  
► Male, aged 64 years, IMD Q4  
► Coronary artery disease  
► 5 parkruns in 1.2 years  
► ≈2 to >4 days per week  
► Evidence of rehabilitation at parkrun |
| 3. Encouragement: support to take part in parkrun (n=13) | a. Parkrun as a whole (n=5) | “The Joy of Park Run is the all inclusive feel it brings to me, as people of all abilities and walks of life all feel to be in one big happy group encouraging each other, to run, jog or walk its such a nice feeling”. (Participant 59876) | ► Long-term committed parkrunner  
► Male, aged 58 years, IMD Q1  
► Heart condition (including arrhythmia/AF)  
► 77 parkruns in 5.2 years  
► >≈2 to >2 days per week  
► Evidence of rehabilitation at parkrun |
| | b. Social support to take part (n=4) | “Even though I can no longer run (Heart failure) parkrun still give me the opportunity to walk with like minded parkrunners. Lots of support from everyone. LOVE IT”. (Participant 2633) | ► Long-term committed parkrunner  
► Male, aged 71 years, IMD Q4  
► Heart failure  
► 302 parkruns in 8.4 years  
► 2 days per week at survey |
| | c. Supported by health professionals (n=5) | “Since starting park run I feel much fitter. Both my cardiologist and GP support me doing this activity. I have noticed that my heart rate has dropped, so much so that I have now been taken off bisoprolol (beta blockers)”. (Participant 85927) | ► Coronary artery disease  
► >≈4 days per week at survey  
► Evidence of rehabilitation at parkrun  
► No other data available |
| 4. Enjoyment: parkrun’s feel-good factor (n=13) | a. Parkrun elicits feelings of joy (n=10) | “Park run give me a feel good factor after the event that last all day”. (Participant 27950) | ► Male, aged 49 years, IMD Q3  
► Heart condition (including arrhythmia/AF)  
► New committed parkrunner  
► 5 parkruns in 0.8 years  
► <≈1 to >3 days per week |

Continued
differences in-depth to identify the individual, social and environmental factors that impact male and female participants with CVD-related conditions engaging in parkrun.

The proportion of individuals with CVD-related conditions increased with 5 km completion time, with almost a quarter of male walkers reporting CVD. The benefits of walking for those with CVD have been found to be largely similar to those of running and parkrun’s introduction of ‘parkwalking’ could be used to attract those with CVD who would otherwise be deterred. Analysis of the open-text comments suggested that some individuals with CVD-related conditions were using parkrun as part of their rehabilitation, either joining following the onset of a medical condition, or returning to parkrun to try to restore previous levels of fitness and health. These individuals reported using parkrun as a focal point to manage and monitor their health, driving confidence and commitment to continue. Feeling part of a community and the social aspects of parkrun were important contributors to their enjoyment.

The ACSM suggests that those in cardiac rehabilitation should do 20–60 min of aerobic exercise 3–5 days per week. Two-thirds of those with CVD-related conditions already undertook 3 or more days of activity per week at parkrun registration, representing a relatively active cohort. Of those undertaking <3 days per week at registration, almost half reported an increase in activity levels in line with the ACSM recommendations. The vast majority reported improvements in their fitness

### Table 2 Continued

<table>
<thead>
<tr>
<th>Theme</th>
<th>Subthemes</th>
<th>Full comments</th>
<th>Participant characteristics</th>
</tr>
</thead>
</table>
| b. Parkrun provides a sense of satisfaction (n=3) | | “After a quite heavy operation in April I have been very pleased to be able to return to park running with only a slight deterioration in my time”. (Participant 24017) | ► New regular parkrunner  
► Male, aged 84 years, IMD Q4  
► Heart condition (including arrhythmia/AF) and hypertension  
► 7 parkruns in 1.1 years  
► ≥2 to ≤1 day per week  
► Evidence of rehabilitation at parkrun |
| a. Managing health conditions: using parkrun to help monitor and manage (n=12) | 5. Managing health conditions: using parkrun to help monitor and manage (n=6) | “My resting heart rate has fallen to the low 40’s from the mid 50’s since starting parkrun. After consultation my my GP, he reduced my dose of bisoprolol (beta blocker) from 5.0mg to 2.5 mg and then to 1.25 mg each time failed to increase my heart rate. I have now been taken off the beta blocker completely and recording a heart rate in the low 50’s. My cardiologist is investigating bradycardia but suggests the low heart rate is probably due to increased fitness levels”. (Participant 47443) | ► New regular parkrunner  
► New committed parkrunner  
► Male, aged 61 years, IMD Q4  
► Coronary artery disease  
► 41 parkruns in 1.0 years  
► ≥4 to ≤4 days per week  
► Evidence of rehabilitation at parkrun |
| b. Monitoring conditions (n=6) | | “I had a pacemaker fitted 14 months ago. Swimming was my sport, but pacemakers do not respond to swimming exercise, they better respond to demands from running. In consultation with cardiology, I completed the C25K course as I used to be a runner, though at my age I would prefer a non impact sport. It seemed logical to try some parkruns to sort of benchmark my progress. At home I have a flat 5.4K course that I try and complete 3–4 times a week. I am still listening to the C25K week 9 podcast. The pacemaker does limit how fast I can run as if I push myself I hit a brick wall where the computer limits my maximum pulse rate to 135bpm. I had a cold recently that stopped me running for 10 days, it took 4 runs to recover to my normal running times”. (Participant 23245) | ► Male aged 67 years, IMD Q1  
► Heart condition (including arrhythmia/AF)  
► 3 parkruns in 0.5 years  
► ≥2 to ≤3 days per week  
► Evidence of rehabilitation at parkrun |
| a. Feelings of frustration (n=5) | | “I was so slow it depressed me, or perhaps that was me, not the way I was treated”. (Participant 15513) | ► New parkrunner  
► Female, aged 75 years, IMD Q3  
► Coronary artery disease  
► Registered 1.9 years  
► ≥3 to ≤4 days per week |
| b. Competing against yourself (n=3) | | “I had heart attack on 4 September and now on appropriate medication. I am slowly building back up my fitness mainly through walking. Will start cycling and golf this week. My goal is to resume park run and better my previous best time”. (Participant 22060) | ► New occasional parkrunner  
► Male, aged 62 years, IMD Q2  
► Heart failure  
► 3 parkruns in 1.0 years  
► ≥3 to ≤3 days per week  
► Evidence of rehabilitation at parkrun |
| c. Parkrun as a low-pressure environment (n=3) | | “A less competitive environment (than a race) has enabled me to check on my health progress following a heart procedure, and it’s side effects”. (Participant 5687) | ► Long-term occasional parkrunner  
► Male, aged 59 years, IMD Q2  
► Heart condition (including arrhythmia/AF) or hypertension  
► 6 parkruns in 5.4 years  
► ≥2 to ≤2 days per week  
► Evidence of rehabilitation at parkrun |

Sample full unedited comments are shown with quotes in bold identifying the part relevant to the theme and subtheme (comments could appear in more than one theme but only in one subtheme within them).

GP, general practitioner.
and physical health following engagement in parkrun, two of the primary motivations for participation. About half of those with CVD-related conditions reported improvements in their ability to control their weight and their overall lifestyle choices, such as diet and smoking. Furthermore, two-thirds of individuals felt that engagement in parkrun enabled them to better manage their health condition. Thus, parkrun may successfully address core elements of cardiac rehabilitation, with the additional benefit of longevity, since parkrun engagement typically lasts years rather than months, far beyond most rehabilitation programmes.

Strengths and limitations
This is the first study to explore whether parkrun is a suitable activity for those with CVD-related conditions and the extensive nature of the survey provides high volume data for both quantitative and qualitative analysis. However, survey responses are limited by their subjective nature and a selection bias reflecting the attitudes of individuals more likely to respond to surveys. As such, the responses obtained may not reflect the overall parkrun population; for example, 13.1% of all parkrun registrants derive from the most deprived IMD quartile compared with 9.2% in this study. Differences between the CVD sample, the no-health conditions sample and the male/ female sample could be confounded by differences in demographic for each subsample. Binomial logistic regression modelling (see online supplemental file S1, tables 5 and 6) indicated that, when these were accounted for, the conclusions of this paper are not changed.

CONCLUSIONS
Individuals with CVD-related conditions participate in parkrun; however, there is scope to increase adoption, especially for female participants. Engagement in parkrun resulted in enhanced fitness and health, with two-thirds reporting improvements to their ability to manage their health conditions and half their ability to manage their weight or lifestyle choices. Qualitative analysis reinforced the benefits of the community aspect of parkrun, the encouragement and confidence it gave and the enjoyment it stimulated. Further research is needed to assess the benefits and enhance healthcare professional engagement in promoting and prescribing exercise. Parkrun, or events with similar characteristics, could support self-managed cardiac rehabilitation.

Acknowledgements We would like to thank Chrisis Wellington and Mike Graney at parkrun for their support in this research and to Tim Chico and Rachel Drew for their helpful suggestions on the manuscript. We would also like to thank all participants who took the time to fill out our survey.

Contributors SH, AB and HQ designed the survey, managed its collection and validated the initial dataset. SH carried out all analysis on the paper and created the first draft. TJW, JB, AB and HQ contributed to further edits and the final manuscript. As guarantor, SH was responsible for the overall content and the decision to publish.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests SH is Chair and AB and HQ are Deputy Chairs of the parkrun Research Board, while other authors are parkrun participants. For the purpose of open access, the authors have applied a Creative Commons Attribution (CC BY) licence to any Author Accepted Manuscript version arising from this submission.

Patient consent for publication Not applicable.

Ethics approval This study was approved by Sheffield Hallam University Research Ethics Committee (ER7034346, 24 July 2018). Participants gave informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; internally peer reviewed.

Data availability statement Data are available in a public, open access repository. Data are available on reasonable request. The datasets used for this study can be found in the Sheffield Hallam University Research Database (SHURDA: DOI: http://doi.org/10.17032/shu-i80637). Access to the full anonymised dataset is possible through the parkrun Research Board, as outlined in original the participant information sheet.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-N C 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD Steve Haake http://orcid.org/0000-0002-4449-6680

REFERENCES
9 O’Doherty AF, Humphreys H, Dawkes S, et al. How has technology been used to deliver cardiac rehabilitation during the COVID-19 pandemic? An international cross-sectional survey of Healthcare professionals conducted by the BACPR. BMJ Open 2021;11:e046051.


